Abstract Search

ea0084ps3-13-120 | Pregnancy & Iodine | ETA2022

The impact of thyroid function on neonatal outcome in women with polycystic ovary syndrome treated with metformin or placebo during pregnancy

Trouva Anastasia , Alvarsson Michael , Calissendorff Jan , Olav AEsvold Bjorn , Linden Hirschberg Angelica , Vanky Eszter

Objectives: Polycystic ovary syndrome (PCOS) and thyroid disorders have separately been linked to adverse pregnancy and neonatal outcomes. Even small variations in thyroid function within the normal range may influence fetal growth. Previous data have shown that metformin-treatment of pregnant women with PCOS reduced late miscarriages and preterm births, and resulted in less decrease of fT4 compared to placebo. Moreover, metformin exposure in utero altered the offspring anthro...

0 shares

ea0099p460 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Polycystic ovary syndrome in type 1 diabetes mellitus: a cross-sectional study of 785 women with diabetes and 1152 controls

Toft Sofia , Rajamand Ekberg Neda , Abdulrahim Hidaya , Linden Hirschberg Angelica , Alvarsson Michael

Background: The prevalence of reproductive disturbances in women with Type 1 Diabetes Mellitus (T1DM) is high compared to the general population. One reason might be higher prevalence of Polycystic ovary syndrome (PCOS) in T1DM. In Sweden, with a high incidence of T1DM, the prevalence of PCOS in women with T1DM is not known. Neither is the T1DM-PCOS pathophysiology.Aim: The aim of this cross-sectional study was to investigate the prevalence of PCOS in a ...

2 shares

ea0099p352 | Reproductive and Developmental Endocrinology | ECE2024

Early response with fezolinetant treatment of moderate-to-severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy: phase 3b daylight study

Linden Hirschberg Angelica , Bouchard Celine , Cano Antonio , Schaudig Katrin , Martins Karla , Miyazaki Kentaro , Wu Xi , Wang Xuegong

Introduction: There is a need for well tolerated and effective nonhormonal therapies for vasomotor symptoms (VMS) associated with menopause. Fezolinetant is a nonhormonal, selective neurokinin 3 receptor antagonist that is approved for the treatment of moderate-to-severe VMS associated with menopause.Objective: To assess how early a response to fezolinetant in frequency and severity of moderate-to-severe VMS was observed in the 24-week placebo-controlled...

2 shares

ea0081rc2.6 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Modified release hydrocortisone capsules (MRHC, Efmody) improve control of congenital adrenal hyperplasia (CAH) on a lower glucocorticoid dose than standard treatment

Rees Aled , Merke Deborah P , Arlt Wiebke , Brac De La Periere Aude , Linden Hirschberg Angelica , Juul Anders , Mallappa Ashwini , Newell-Price John D. C. , Graham Perry Colin , Prete Alessandro , Reisch Nicole , Stikkelbroeck Monica , Touraine Philippe A , Coope Helen , Porter John , Ross Richard John M

Background: The therapeutic goal in CAH is androgen control on the lowest achievable glucocorticoid dose, preferably an adrenal replacement dose (15-25 mg hydrocortisone a day)1. However, the glucocorticoid dose required to control androgens frequently exceeds that required for adrenal replacement2. Modified-release hydrocortisone (MRHC) capsules, (Efmody, Diurnal Ltd, Cardiff, UK), replicate cortisol diurnal rhythm and improve CAH control compared to sta...

4 shares

ea0081rc2.7 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Improved biochemical control with modified-release hydrocortisone overturns the impaired fludrocortisone effect in salt-wasting CAH patients

Tschaidse Lea , Reisch Nicole , Arlt Wiebke , Brac De La Perriere Aude , Linden Hirschberg Angelica , Juul Anders , Mallappa Ashwini , Merke Deborah P , Newell-Price John DC , Perry Colin Graham , Prete Alessandro , Rees Aled , Stikkelbroeck Monica , Touraine Phillippe A , Coope Helen , Porter John , Ross Richard John M , Quinkler Marcus

Background: Patients with salt-wasting congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency require glucocorticoid (GC) and mineralocorticoid (MC) replacement therapy. Recently, it was shown that twice daily modified-release hydrocortisone hard capsules (MRHC, Efmody®, Diurnal Ltd) improved control of CAH with most patients showing good disease control versus standard GC therapy. However, no data has been reported on the renin-angiotens...

1 shares

ea0081rc2.8 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Fertility in congenital adrenal hyperplasia (CAH) patients on modified release hydrocortisone capsules (MRHC, Efmody)

Tschaidse Lea , Quinkler Marcus , Arlt Wiebke , Brac De La Perriere Aude , Linden Hirschberg Angelica , Juul Anders , Mallappa Ashwini , Merke Deborah P , Newell-Price John DC , Perry Colin Graham , Prete Alessandro , Rees Aled , Stikkelbroeck Monica , Touraine Philippe A , Coope Helen , Porter John , Ross Richard John M , Reisch Nicole

Background: Fertility in CAH women is impaired: 0.25 live births vs 1.8 in the UK population and 45% have irregular menses vs 13.6% in healthy women1. Male fertility is also impaired in CAH with oligospermia reported in 48%2. Treatment of infertility usually involves increasing the glucocorticoid dose to normalise adrenal androgens and progesterone to facilitate ovulation and implantation, respectively. Modified-release hydrocortisone (MRHC) capsules, (Ef...

3 shares

ea0090oc5.3 | Oral Communications 5: Adrenal and Cardiovascular Endocrinology 1 | ECE2023

Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control

Ross Richard John M , Rees Aled , P. Merke Deborah , Arlt Wiebke , Brac De La Perriere Aude , Linden Hirschberg Angelica , Juul Anders , D. C. Newell-Price John , Perry Colin Graham , Prete Alessandro , Reisch Nicole , Stikkelbroeck Monica , A. Touraine Philippe , Mallappa Ashwini , Aslam Naila , Coope Helen , Porter John

Background: Modified-release hydrocortisone (MRHC) capsules (Efmody, Diurnal Ltd, Cardiff, UK), have been developed to replicate the cortisol diurnal rhythm and shown to improve CAH disease control1. We have examined relative bioavailability of MRHC and disease control of congenital adrenal hyperplasia (CAH) patients switched from standard therapy to MRHC.Methods: An open label, randomised, 2 period, crossover study comparing the relative bioavailability...

5 shares

Endocrine Abstracts